{ "company": "Hologic", "ticker": "HOLX", "period": { "from": "2026-03-08", "to": "2026-04-07", "days": 30 }, "sentiment_breakdown": { "positive": 41, "negative": 28, "neutral": 55 }, "synthesis": { "executive_summary": "Sentiment analysis for Hologic (HOLX) from 2026-03-08 to 2026-04-07. Analyzed 124 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "Masimo Corp Stock: Innovative Medical Tech Leader with Strong Growth Potential for North American In", "date": "2026-03-29", "source": "alpha_vantage", "score": 1.0 }, { "title": "Mammography Workstation Market to Grow by $500 Million During 2026-2030 Led by Siemens Healthineers, Fujifilm, and Koninklijke Philips", "date": "2026-04-01", "source": "news", "score": 1.0 }, { "title": "COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "date": "2026-03-12", "source": "news", "score": 0.859 }, { "title": "Hologic stock sees fresh institutional interest as Pensionfund Sabic buys 18,800 shares amid medical", "date": "2026-03-26", "source": "alpha_vantage", "score": 0.758 }, { "title": "Hologic stock sees fresh institutional interest as Pensionfund Sabic buys 18,800 shares amid medical", "date": "2026-03-26", "source": "alpha_vantage", "score": 0.758 }, { "title": "InMode Ltd Stock: Innovative Aesthetic Devices Driving Growth in a Competitive Medical Tech Landscap", "date": "2026-04-02", "source": "alpha_vantage", "score": 0.735 }, { "title": "Global Women's Health Shows Signs of Progress; Gaps Remain", "date": "2026-03-17", "source": "news", "score": 0.7 }, { "title": "U.S. Exosomes Market to Skyrocket During 2026-2033, Reaching $716.8 Million - Analysis of Lucrative Business Opportunities and Key Players; Danaher, Thermo Fisher Scientific, Hologic, Fujifilm, Lonza and More", "date": "2026-03-20", "source": "news", "score": 0.681 }, { "title": "Biomarker Testing Market Projected to Reach USD 50.76 Billion by 2035, Driven by Personalized Medicine and Oncology Advancements – SNS Insider", "date": "2026-03-10", "source": "news", "score": 0.66 }, { "title": "Global Point-of-Care Molecular Diagnostics Market Projected to Reach USD 13.05 Billion by 2035; Growth is Driven by Increasing Need for Fast Near-Patient Testing Globally – SNS Insider", "date": "2026-03-09", "source": "news", "score": 0.625 } ], "top_negative": [ { "title": "Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.", "date": "2026-04-07", "source": "pubmed", "score": -0.898 }, { "title": "Mammography Devices Market to Reach $3.81 Billion by 2030, Driven by Technological Advancements and Rising Breast Cancer Awareness", "date": "2026-03-27", "source": "news", "score": -0.727 }, { "title": "Dual-modality CAD for breast cancer screening: dealing with discordant diagnosis between mammography and tomography.", "date": "2026-04-07", "source": "pubmed", "score": -0.66 }, { "title": "Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.66 }, { "title": "Clinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.66 }, { "title": "Late distant recurrence prediction model in premenopausal women with ER-positive/HER 2-negative breast cancer: A multicenter retrospective study.", "date": "2026-04-07", "source": "pubmed", "score": -0.66 }, { "title": "DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.66 }, { "title": "Validation of a Low-Volume (100 μL) Plasma Protocol for HIV-1 RNA Quantification Using the Hologic Aptima HIV-1 Quant Dx Assay.", "date": "2026 Apr 3", "source": "pubmed", "score": -0.612 }, { "title": "Biopsy Devices Market Size Projected to Reach USD 5.08 Billion by 2035; Increasing Incidence of Cancer to Drive Market Growth Globally – SNS Insider", "date": "2026-03-20", "source": "news", "score": -0.572 }, { "title": "Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review.", "date": "2026-04-07", "source": "pubmed", "score": -0.542 } ], "raw_data": { "total_items": 124, "items": [ { "source": "alpha_vantage", "title": "Casey’s General Stores Joining S&P 500 This Week", "url": "https://www.barrons.com/articles/caseys-general-stores-joining-s-p-500-770c6eac?gaa_at=eafs&gaa_n=AWEtsqfpREw576bAPhAuJ5r5hIE6_7llXSuNIuhWSz7sKb0OLc6aYoF9fj3D&gaa_ts=69d4394f&gaa_sig=w9E_Y_3g65whud1w6F23w_mahTNrKyIN9G1XMn5fma85u0DkhYdFqLses8NdQx6JKyhod_7RrKu84rXdcUbcuw%3D%3D", "date": "2026-04-06", "summary": "Casey's General Stores (CASY) is set to join the S&P 500 index, replacing Hologic Inc. (HOLX). This change, announced by S&P Dow Jones Indices, will take effect before trading opens on Thursday.", "sentiment_score": -0.364617, "sentiment_label": "Bearish", "relevance_score": 0.83048, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Blackstone (BX) and TPG Global Partner to Acquire Hologic", "url": "https://www.gurufocus.com/news/8776878/blackstone-bx-and-tpg-global-partner-to-acquire-hologic", "date": "2026-04-06", "summary": "Blackstone (BX) and TPG Global are partnering to acquire Hologic, a strategic move reinforcing Blackstone's expansion in the healthcare sector. Despite recent stock price declines, Blackstone, the world's largest alternative-asset manager with $1.275 trillion in assets under management, maintains strong financial health marked by robust revenue growth and profitability. The acquisition highlights Blackstone's growth ambitions, though investors should consider its moderate leverage and higher mar", "sentiment_score": 0.220975, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.83214, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "S&P Dow Jones Indices says Casey's General Stores Inc. will replace Hologic Inc. in the S&P 500 effective prior to the market open on April 9", "url": "https://www.marketscreener.com/news/s-p-dow-jones-indices-says-casey-s-general-stores-inc-will-replace-hologic-inc-in-the-s-p-500-effe-ce7e51d3d88bfe24", "date": "2026-04-06", "summary": "S&P Dow Jones Indices announced that Casey's General Stores Inc. will be added to the S&P 500 index, replacing Hologic Inc. This change will become effective before the market opens on April 9. The report was published on Reuters and MarketScreener.", "sentiment_score": -0.257549, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "S&P Dow Jones Indices Says Casey's General Stores Inc. Will Replace Hologic Inc. In The S&P 500 Effective Prior To The Market Open On April 9", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN40N02A:0-s-p-dow-jones-indices-says-casey-s-general-stores-inc-will-replace-hologic-inc-in-the-s-p-500-effective-prior-to-the-market-open-on-april-9/", "date": "2026-04-06", "summary": "S&P Dow Jones Indices has announced that Casey's General Stores Inc. (CASY) will replace Hologic Inc. (HOLX) in the S&P 500 index. This change will be effective prior to the market open on April 9. The article provides key information regarding the upcoming S&P 500 component change.", "sentiment_score": 0.34155, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.923474, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Hologic Inc stock hits 52-week high at $76.01 By Investing.com", "url": "https://ca.investing.com/news/company-news/hologic-inc-stock-hits-52week-high-at-7601-93CH-4550425", "date": "2026-04-06", "summary": "Hologic Inc. stock reached a new 52-week high of $76.01, reflecting strong investor confidence and a 24.3% return over the past year. Despite recent fiscal first-quarter earnings missing analyst expectations, the company is undergoing significant corporate developments, including an acquisition by Blackstone and TPG, and FDA approval for its Aptima HPV Assay, signaling a period of strategic change and growth.", "sentiment_score": 0.421411, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Encompass Health Corp Stock (EHC) Moved Up by 7.51% on Apr 6: What Signal Does It Send?", "url": "https://www.tradingkey.com/news/Market-Movers/261754526-market-movers-ehc-20260406", "date": "2026-04-06", "summary": "Encompass Health Corp (EHC) saw its stock rise by 7.51% on April 6, driven by a proposed increase in payment rates for rehabilitation hospitals by CMS and positive \"Overweight\" ratings from analysts like KeyBanc and Barclays. This upward movement occurred despite a recent securities fraud investigation, suggesting the market prioritized the favorable regulatory and analyst news. The company's strong Q4 2025 results also provided a positive financial foundation.", "sentiment_score": 0.12983, "sentiment_label": "Neutral", "relevance_score": 0.602522, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic CEO Steve MacMillan to retire after go-private deal", "url": "https://www.medtechdive.com/news/hologic-ceo-steve-macmillan-to-retire-after-go-private-deal/816710/", "date": "2026-04-06", "summary": "Hologic CEO Steve MacMillan will retire following the company's acquisition by Blackstone and TPG for $18.3 billion. The deal is set to close on Tuesday after receiving all necessary regulatory approvals. MacMillan led Hologic for 13 years, significantly increasing revenue and share price, and will be succeeded by a new CEO named upon the acquisition's completion.", "sentiment_score": -0.234024, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) CEO Announces Retirement Amid Upcoming Transaction", "url": "https://www.gurufocus.com/news/8775976/hologic-holx-ceo-announces-retirement-amid-upcoming-transaction", "date": "2026-04-06", "summary": "Hologic (HOLX) CEO Steve MacMillan is retiring following the completion of a go-private transaction with Blackstone and TPG, which is expected to finalize around April 7, 2026. The company, specializing in women's healthcare diagnostics and medical devices, shows strong profitability despite declining revenue growth. Its financial health appears robust, with high institutional ownership and a neutral market sentiment.", "sentiment_score": -0.099303, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic Inc stock hits 52-week high at $76.01 By Investing.com", "url": "https://in.investing.com/news/company-news/hologic-inc-stock-hits-52week-high-at-7601-93CH-5324153", "date": "2026-04-06", "summary": "Hologic Inc. stock reached a new 52-week high of $76.01, demonstrating strong investor confidence in the medical technology company with a 24.3% return over the past year. This comes despite recent Q1 earnings missing analyst expectations, while the company also prepares for a CEO transition and celebrates FDA approval for its Aptima HPV Assay. InvestingPro analysis indicates the stock is fairly valued and has a \"GREAT\" financial health rating.", "sentiment_score": 0.347286, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic CEO Steve MacMillan to Retire After Private Equity Deal", "url": "https://www.mpo-mag.com/breaking-news/hologic-ceo-steve-macmillan-to-retire-after-private-equity-deal/", "date": "2026-04-06", "summary": "Hologic CEO Steve MacMillan has announced his retirement following the impending closure of the $18.3 billion go-private transaction with Blackstone and TPG. During his 12-plus years, Hologic's revenue grew 65% and its share price increased 241%. The transaction is expected to close on or about April 7, 2026, with a new CEO to be announced afterward.", "sentiment_score": 0.112544, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic Inc stock hits 52-week high at $76.01", "url": "https://www.investing.com/news/company-news/hologic-inc-stock-hits-52week-high-at-7601-93CH-4598716", "date": "2026-04-06", "summary": "Hologic Inc.'s stock reached a new 52-week high of $76.01, indicating strong investor confidence and a 24.3% return over the past year. Despite slightly missing Q1 earnings estimates, the company is undergoing a CEO transition and recently gained FDA approval for its Aptima HPV Assay for primary screening, signaling ongoing strategic developments. InvestingPro analysis suggests the stock is fairly valued with a \"GREAT\" financial health score.", "sentiment_score": 0.1055, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic CEO Steve MacMillan To Retire", "url": "https://www.citybiz.co/article/828349/hologic-ceo-steve-macmillan-to-retire/", "date": "2026-04-06", "summary": "Hologic, Inc. announced that CEO Steve MacMillan will retire following the company's go-private transaction with Blackstone and TPG, expected to close around April 7, 2026. MacMillan's 12-plus year tenure saw significant growth in revenue, earnings per share, and stock price, along with the company's response to the COVID pandemic. The board and MacMillan expressed gratitude for his leadership, and a new CEO is expected to be announced upon the transaction's close.", "sentiment_score": 0.204286, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic's Stephen P. MacMillan to Retire as CEO and Chairman upon Blackstone/TPG Acquisition Close", "url": "https://www.tradingview.com/news/tradingview:ed6040e550c7c:0-hologic-s-stephen-p-macmillan-to-retire-as-ceo-and-chairman-upon-blackstone-tpg-acquisition-close/", "date": "2026-04-06", "summary": "Stephen P. MacMillan, the President, CEO, and Chairman of Hologic (HOLX), will retire from his positions immediately following the closing of the company's acquisition by affiliates of funds managed by Blackstone and TPG. This decision was informed to the Board and is effective upon the merger's completion. The information was disclosed in an SEC filing (8-K) on April 6, 2026.", "sentiment_score": 0.014724, "sentiment_label": "Neutral", "relevance_score": 0.341593, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Hologic (NASDAQ: HOLX) CEO exit tied to Blackstone, TPG buyout", "url": "https://www.stocktitan.net/sec-filings/HOLX/8-k-hologic-inc-reports-material-event-3323f34917b3.html", "date": "2026-04-06", "summary": "Hologic, Inc. announced that CEO Steve MacMillan will retire immediately upon the closing of its go-private merger with affiliates of Blackstone and TPG, which is expected around April 7, 2026. All necessary regulatory approvals have been secured for the transaction. MacMillan's 12-year tenure saw significant growth in revenue, EPS, and share price, and his successor is anticipated to be announced upon the merger's completion.", "sentiment_score": 0.103796, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic's CEO will retire as Blackstone-TPG buyout nears close", "url": "https://www.stocktitan.net/news/HOLX/hologic-chief-executive-officer-steve-mac-millan-to-retire-upon-bdzmbk4ybw09.html", "date": "2026-04-06", "summary": "Hologic, Inc. announced that its long-time Chairman, President, and CEO, Steve MacMillan, will retire upon the closing of its go-private transaction with Blackstone and TPG. The transaction is expected to close around April 7, 2026, after receiving all necessary regulatory approvals. MacMillan led Hologic for over 12 years, during which the company saw significant growth in revenue, non-GAAP earnings per share, share price, and workforce.", "sentiment_score": 0.012045, "sentiment_label": "Neutral", "relevance_score": 0.319252, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript", "url": "https://www.insidermonkey.com/blog/volitionrx-limited-amexvnrx-q4-2025-earnings-call-transcript-1731677/", "date": "2026-04-04", "summary": "VolitionRx Limited (AMEX:VNRX) reported strong Q4 and full-year 2025 results, with 40% revenue growth driven by its Nu.Q Discover platform and initial sales of Nu.Q NETs products. The company highlighted significant progress in commercializing its Nu.Q platform for human diagnostics, including partnerships with Werfen and Hologic, and critical advancements in feline cancer detection and a novel Capture-Seq technology for pure circulating tumor DNA. VolitionRx is shifting its strategic focus from", "sentiment_score": 0.262351, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.6268, "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "alpha_vantage", "title": "At Harvard gala, QT Imaging CEO pushes earlier breast cancer detection", "url": "https://www.stocktitan.net/news/QTI/qt-imaging-ceo-discusses-the-importance-of-early-breast-cancer-0y2h937dq3by.html", "date": "2026-04-02", "summary": "QT Imaging Holdings, Inc. CEO Dr. Raluca Dinu participated in the inaugural Shiftmakers Gala at Harvard University, highlighting the importance of early breast cancer detection. Dinu emphasized that their radiation-free imaging technology addresses the challenge of dense breast tissue, which often makes mammography alone insufficient for many women. The event, supported by Gloria Steinem, focused on women driving change, and QT Imaging's work will be featured in The Shift to further promote awar", "sentiment_score": 0.104134, "sentiment_label": "Neutral", "relevance_score": 0.647048, "sentiment": { "label": "negative", "score": -0.218, "confidence": 0.22 } }, { "source": "alpha_vantage", "title": "ResMed Inc. (RMD) stock price, news, quote and history", "url": "https://sg.finance.yahoo.com/quote/RMD/", "date": "2026-04-02", "summary": "This article provides comprehensive financial data, news, and historical information for ResMed Inc. (RMD). It includes real-time stock quotes, key statistics, performance over various periods, an overview of the company's operations in medical devices and cloud-based software, and analyst insights. The report also lists financial highlights, profitability metrics, and allows for comparison with similar companies in the Medical Instruments & Supplies industry.", "sentiment_score": 0.001698, "sentiment_label": "Neutral", "relevance_score": 0.679904, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Biopsy Devices Market to Reach US$ 6.85 Billion by 2033 at 10.15% CAGR; North America Leads with 42% Share - Key Players: Becton, Dickinson and Company, Hologic Inc., Boston Scientific Corporation", "url": "https://www.openpr.com/news/4452715/biopsy-devices-market-to-reach-us-6-85-billion-by-2033-at-10-15", "date": "2026-04-02", "summary": "The global biopsy devices market is projected to reach US$ 6.85 billion by 2033, growing at a compound annual growth rate (CAGR) of 10.15% from US$ 2.68 billion in 2025. This growth is primarily driven by the increasing prevalence of cancer and other chronic diseases, alongside advancements in minimally invasive and image-guided biopsy technologies. North America is expected to maintain its leading position in the market, holding a 42% share, due to its advanced healthcare infrastructure and ear", "sentiment_score": 0.309501, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.90688, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Mammography Machine Market is expected to Hit US$ 4.1 billion by 2033 | Major Companies - GE HealthCare, Hologic, Inc., PLANMED OY, Carestream Health", "url": "https://www.openpr.com/news/4452064/mammography-machine-market-is-expected-to-hit-us-4-1-billion", "date": "2026-04-02", "summary": "The global Mammography Machine Market, valued at US$ 2.6 billion in 2024, is projected to reach US$ 4.1 billion by 2033, demonstrating a CAGR of 5.1% from 2025 to 2033. This growth is driven by increasing breast cancer awareness, technological advancements, and a rising demand for early detection solutions. Key players in this market include GE HealthCare, Hologic, Inc., and FUJIFILM Holdings Corporation, with recent developments focusing on 3D tomosynthesis, AI-powered tools, and strategic acqu", "sentiment_score": 0.335524, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.94321, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "InMode Ltd Stock: Innovative Aesthetic Devices Driving Growth in a Competitive Medical Tech Landscap", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/inmode-ltd-stock-innovative-aesthetic-devices-driving-growth-in-a/69054828", "date": "2026-04-02", "summary": "InMode Ltd specializes in non-invasive aesthetic medical devices, utilizing radiofrequency and laser technologies for treatments like body contouring and skin rejuvenation. The company's business model involves selling capital equipment and generating recurring revenue from consumables, with a significant global footprint. Despite strong growth and an innovative product lineup, investors should monitor regulatory hurdles, competition, economic downturns, and supply chain disruptions.", "sentiment_score": 0.125554, "sentiment_label": "Neutral", "relevance_score": 0.578858, "sentiment": { "label": "positive", "score": 0.735, "confidence": 0.74 } }, { "source": "alpha_vantage", "title": "Quantum-Si (NASDAQ: QSI) plans 2026 virtual meeting and pay vote", "url": "https://www.stocktitan.net/sec-filings/QSI/def-14a-quantum-si-inc-definitive-proxy-statement-d8c8792f6cd4.html", "date": "2026-04-01", "summary": "Quantum-Si (NASDAQ: QSI) will hold its fully virtual 2026 annual shareholder meeting on May 15, 2026, at 1:00 p.m. Eastern, where stockholders will vote on electing ten directors, ratifying PricewaterhouseCoopers LLP as auditor, and approving a non-binding advisory say-on-pay for named executive officers. Founder Jonathan M. Rothberg, Ph.D., who beneficially owns all Class B shares, holds approximately 69.33% of the total voting power, effectively controlling the outcome of all proposals. The pr", "sentiment_score": 0.034094, "sentiment_label": "Neutral", "relevance_score": 0.61391, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Emerging Sub-Segments Transforming the Medical Device Subscription Market Landscape", "url": "https://www.openpr.com/news/4450971/emerging-sub-segments-transforming-the-medical-device", "date": "2026-04-01", "summary": "The medical device subscription market is projected to reach $24.89 billion by 2030, growing at a CAGR of 22.5%, driven by remote monitoring, AI, and telehealth integration. Key players like Thermo Fisher Scientific and Medtronic are shaping the industry, with innovations like next-generation health wearables fostering personalized wellness management. The market is segmented by device type, subscription model, application, and end-user, including diagnostic, therapeutic, and monitoring devices ", "sentiment_score": 0.32777, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.744493, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Competitive Analysis: Key Market Leaders and New Entrants in the Lyme Disease Testing Industry", "url": "https://www.openpr.com/news/4450845/competitive-analysis-key-market-leaders-and-new-entrants-in", "date": "2026-04-01", "summary": "The Lyme disease testing market is projected to reach $16.46 billion by 2030, growing at a CAGR of 9.0%, driven by advancements in diagnostics and increased awareness of tick-borne illnesses. Key trends include AI-assisted tools, home-testing kits, and multi-disease panels. Companies like Roche, Thermo Fisher Scientific, and Quest Diagnostics are leading innovation, with strategic partnerships and technological advancements enhancing early and precise detection methods.", "sentiment_score": 0.283837, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.611305, "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "alpha_vantage", "title": "Retirement Systems of Alabama Decreases Stock Holdings in Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-retirement-systems-of-alabama-decreases-stock-holdings-in-hologic-inc-holx-2026-04-01/", "date": "2026-04-01", "summary": "Retirement Systems of Alabama significantly reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 47.7% in the fourth quarter, selling over 332,000 shares and retaining a holding valued at $27.13 million. This move follows Hologic missing its Q4 earnings expectations and several analysts downgrading the stock, resulting in a consensus \"Hold\" rating with an average price target of $78.42. Institutional investors collectively own 94.73% of the company's stock.", "sentiment_score": -0.298978, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic, Inc. (HOLX) Is Gaining Attention: Key Information to Consider Before Investing", "url": "https://www.bitget.com/amp/news/detail/12560605322269", "date": "2026-03-31", "summary": "Hologic, Inc. (HOLX) is drawing investor attention, prompting a review of its recent performance, earnings trends, and valuation. Despite a slight increase in share price over the last month, its Zacks Rank #4 (Sell) suggests potential underperformance against the broader market. Investors should consider these fundamental factors alongside its recent financial results and revenue growth outlook.", "sentiment_score": -0.137386, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Hologic, Inc. (HOLX) Is Gaining Attention: Key Information to Consider Before Investing", "url": "https://www.bitget.com/news/detail/12560605322269", "date": "2026-03-30", "summary": "Hologic, Inc. (HOLX) is drawing investor attention, prompting a review of its recent performance, earnings estimates, and valuation. Despite a slight increase in share price over the past month, the company's Zacks Rank #4 (Sell) suggests potential underperformance in the near future. While earnings and revenue estimates show growth, recent financial results missed consensus expectations.", "sentiment_score": 0.063849, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "CIBRA Capital Ltd Purchases Shares of 62,838 Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-cibra-capital-ltd-purchases-shares-of-62838-hologic-inc-holx-2026-03-29/", "date": "2026-03-29", "summary": "CIBRA Capital Ltd initiated a new position in Hologic, Inc. (NASDAQ:HOLX) during Q4, acquiring 62,838 shares valued at approximately $4.68 million, making HOLX its sixth-largest holding. Despite 2.5% year-over-year revenue growth, Hologic missed recent quarterly estimates. Analysts primarily rate the stock as a \"Hold\" with an average price target of $78.42, while shares trade near their 52-week high.", "sentiment_score": 0.034167, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Nordea Investment Management AB Has $1.74 Million Holdings in Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-nordea-investment-management-ab-has-174-million-holdings-in-hologic-inc-holx-2026-03-29/", "date": "2026-03-29", "summary": "Nordea Investment Management AB significantly reduced its stake in Hologic, Inc. by 99.2% in Q4, leaving them with 23,325 shares valued at $1.739 million. This reduction comes as Hologic missed Q4 earnings expectations with EPS of $1.04 against a $1.09 forecast and revenue of $1.05 billion versus $1.07 billion projected. Following these results, several brokers have downgraded the stock, leading to a consensus \"Hold\" rating and a target price of $78.42.", "sentiment_score": -0.265283, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Masimo Corp Stock: Innovative Medical Tech Leader with Strong Growth Potential for North American In", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/masimo-corp-stock-innovative-medical-tech-leader-with-strong-growth/69024469", "date": "2026-03-29", "summary": "Masimo Corp is highlighted as a leading innovator in noninvasive patient monitoring, offering robust growth potential for North American investors. The article details its core business model, technological leadership in pulse oximetry and advanced sensors, and strong market positioning against competitors. It also covers the company's financial health, innovation pipeline, and strategic outlook, while acknowledging risks inherent in the medtech industry.", "sentiment_score": 0.131871, "sentiment_label": "Neutral", "relevance_score": 0.557656, "sentiment": { "label": "positive", "score": 1.0, "confidence": 1.0 } }, { "source": "alpha_vantage", "title": "CIBRA Capital Ltd Acquires Stake in Hologic, Inc.", "url": "https://nationaltoday.com/us/ma/marlborough/news/2026/03/29/cibra-capital-ltd-acquires-stake-in-hologic-inc/", "date": "2026-03-29", "summary": "CIBRA Capital Ltd has acquired 62,838 shares of Hologic, Inc. (NASDAQ:HOLX) stock, valued at approximately $4.68 million, representing a new position for the investment firm. This move highlights CIBRA Capital's confidence in Hologic's market position and growth potential in the women's health sector. The investment firm now holds Hologic as its sixth-largest holding, comprising 8% of its total portfolio.", "sentiment_score": 0.456459, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Inside 'Project Eagle,' JPMorgan's high-wire act to fund $55 bn EA deal", "url": "https://www.business-standard.com/world-news/inside-project-eagle-jpmorgan-s-high-wire-act-to-fund-55-bn-ea-deal-126032900068_1.html", "date": "2026-03-29", "summary": "JPMorgan Chase successfully navigated volatile markets and geopolitical tensions to fund the $55 billion private equity takeover of Electronic Arts (EA), an operation code-named 'Project Eagle.' The deal, which involved selling $6.4 billion in bonds and an $8.125 billion leveraged loan, was pushed forward quickly after a social media post from President Donald Trump offered a brief window of market calm. Despite soaring inflation and concerns over software company valuations, strong investor dem", "sentiment_score": 0.246311, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.614251, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic stock consolidates as company recognized among America's most charitable firms", "url": "https://tradersunion.com/news/companies/show/1816666-hologic-slips-0-03percent-today-at/", "date": "2026-03-29", "summary": "Hologic's stock is consolidating around new highs, currently trading at $75.67, amidst its recognition on Newsweek's list of America's Most Charitable Companies for its dedication to women's health, STEM, and education. Technical analysis indicates a strong bullish trend with price above key moving averages, though some oscillators suggest potential overbought conditions. The stock has risen 0.34% over the past week and is expected to trade between $75.70 and $75.92 in the coming week, with a hi", "sentiment_score": 0.329786, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.458, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Assessing Hologic (HOLX) Valuation After A 21% One Year Shareholder Return", "url": "https://www.sahmcapital.com/news/content/assessing-hologic-holx-valuation-after-a-21-one-year-shareholder-return-2026-03-27", "date": "2026-03-28", "summary": "Hologic (HOLX) has seen a 21% shareholder return over the past year, with shares currently trading around US$75.69. Despite this performance, Simply Wall St's analysis suggests the stock is slightly undervalued, with a fair value estimated at $76.67 per share. The valuation takes into account long-term growth drivers in women's health and diagnostics, but acknowledges potential risks like tariff costs and pressure in international markets.", "sentiment_score": 0.287679, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "THE COOPER Cyclically Adjusted PB Ratio: 2.20 — 50% Below", "url": "https://www.gurufocus.com/term/cyclically_adjusted_pb/COO", "date": "2026-03-27", "summary": "The Cooper Companies Inc's (COO) Cyclically Adjusted PB Ratio currently stands at 2.26, which is 48% below its 10-year median of 4.37. GuruFocus rates COO with a GF Score of 96/100 and a GF Value of $102.22, indicating it is significantly undervalued despite having two warning signs for investors. The company's Cyclically Adjusted Book per Share for January 2026 was $31.64, and its current share price is $71.43.", "sentiment_score": 0.101594, "sentiment_label": "Neutral", "relevance_score": 0.644895, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Align Technology (ALGN) $4.0B 2025 revenue, board refreshment and 2026 proxy", "url": "https://www.stocktitan.net/sec-filings/ALGN/pre-14a-align-technology-inc-preliminary-proxy-statement-963d2a9a5342.html", "date": "2026-03-27", "summary": "Align Technology's 2026 Proxy Statement details its 2025 financial results, including $4.0 billion in net revenues, and outlines strategic priorities such as international expansion and AI-enabled treatment enhancements. The company is also proposing governance changes, including board refreshment and adjustments to executive compensation to better align with stockholder interests. Stockholders will vote on these proposals, as well as the election of ten directors and the ratification of the ind", "sentiment_score": 0.120477, "sentiment_label": "Neutral", "relevance_score": 0.605091, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "ALGN (Align Technology) Net Change in Cash : $51 Mil (TTM As of Dec. 2025)", "url": "https://www.gurufocus.com/term/Net+Change+in+Cash/NAS:ALGN", "date": "2026-03-27", "summary": "Align Technology (ALGN) recorded a Net Change in Cash of $51 million for the trailing twelve months (TTM) ended December 2025, and $90 million for the quarter ended December 2025. GuruFocus assesses ALGN with a GF Score of 89/100 and a GF Value of $249.91, indicating it is significantly undervalued compared to its current price of $166.38, despite having six warning signs for investors. The article details the calculation of Net Change in Cash and provides historical data and comparisons for the", "sentiment_score": 0.032318, "sentiment_label": "Neutral", "relevance_score": 0.555755, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Vanguard (HOLX) amendment shows 0 shares after Jan 12, 2026 realignment", "url": "https://www.stocktitan.net/sec-filings/HOLX/schedule-13g-a-hologic-inc-amended-passive-investment-disclosure-53cf00ba97e3.html", "date": "2026-03-27", "summary": "The Vanguard Group filed an amendment to its Schedule 13G/A, reporting 0 shares of Hologic Inc Common Stock. This change follows an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries and business divisions will now report beneficial ownership separately, relying on SEC Release No. 34-39538. The filing confirms Vanguard directly holds 0 shares and 0% of the class, with no single outside person known to hold more than 5%.", "sentiment_score": 0.01352, "sentiment_label": "Neutral", "relevance_score": 0.347783, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Syquant Capital Sas Purchases New Stake in Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-syquant-capital-sas-purchases-new-stake-in-hologic-inc-holx-2026-03-27/", "date": "2026-03-27", "summary": "Syquant Capital Sas has acquired a new stake in Hologic, Inc. (HOLX) during the fourth quarter, purchasing 126,300 shares valued at approximately $9.41 million. This makes Hologic about 1.2% of Syquant's portfolio. Institutional ownership of Hologic is high at 94.73%, and while analysts generally issue a \"Hold\" rating with a consensus price target of $78.42, the company recently missed quarterly earnings and revenue estimates.", "sentiment_score": -0.21621, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "SG Americas Securities LLC Purchases 337,882 Shares of Hologic, Inc. $HOLX", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-purchases-337882-shares-of-hologic-inc-holx-2026-03-26/", "date": "2026-03-27", "summary": "SG Americas Securities LLC significantly increased its stake in Hologic, Inc. by 405.3% during the fourth quarter, purchasing 337,882 additional shares to hold a total of 421,240 shares valued at approximately $31.38 million. Despite this institutional buying, analyst sentiment for Hologic remains mixed, with an average \"Hold\" rating and a price target of $78.42, following recent downgrades and a slight earnings miss. The company's stock performance shows a 50-day moving average of $75.20 and a ", "sentiment_score": -0.105488, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "Pensionfund Sabic Takes $1.11 Million Position in Quest Diagnostics Incorporated $DGX", "url": "https://www.marketbeat.com/instant-alerts/filing-pensionfund-sabic-takes-111-million-position-in-quest-diagnostics-incorporated-dgx-2026-03-26/", "date": "2026-03-26", "summary": "Pensionfund Sabic initiated a new position in Quest Diagnostics (NYSE:DGX) in Q4, acquiring 6,400 shares valued at approximately $1.11 million. This move comes as Quest Diagnostics exceeded Q4 earnings expectations, announced a $1.0 billion share repurchase program, and raised its quarterly dividend. Analysts currently rate the stock with a consensus \"Moderate Buy\" and an average price target of $210.29.", "sentiment_score": 0.118042, "sentiment_label": "Neutral", "relevance_score": 0.618956, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic stock sees fresh institutional interest as Pensionfund Sabic buys 18,800 shares amid medical", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/hologic-stock-sees-fresh-institutional-interest-as-pensionfund-sabic-buys/68988633", "date": "2026-03-26", "summary": "Pensionfund Sabic recently acquired 18,800 shares of Hologic Inc (ISIN: US4364401012), signaling confidence in the women's health diagnostics leader. This move highlights the stock's appeal amid broader market rotations toward defensive healthcare plays, with Hologic specializing in women's health products like mammography systems and cervical cancer screening tools. The acquisition by a major Dutch pension fund suggests conviction in the company's long-term growth and stable returns, particular", "sentiment_score": 0.629671, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.758, "confidence": 0.76 } }, { "source": "alpha_vantage", "title": "Hologic stock sees fresh institutional interest as Pensionfund Sabic buys 18,800 shares amid medical", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-sees-fresh-institutional-interest-as-pensionfund-sabic-buys/68988633", "date": "2026-03-26", "summary": "Pensionfund Sabic has acquired 18,800 shares of Hologic Inc., a women's health diagnostics leader, indicating institutional confidence in the company's long-term growth. This move highlights Hologic's appeal as a resilient medtech segment play, benefiting from predictable cash flows, high barriers to entry, and essential healthcare demand. The purchase aligns with a broader trend of pension funds seeking stable returns from companies like Hologic, which generate recurring revenue from consumable", "sentiment_score": 0.432366, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.758, "confidence": 0.76 } }, { "source": "alpha_vantage", "title": "18,800 Shares in Hologic, Inc. $HOLX Bought by Pensionfund Sabic", "url": "https://www.marketbeat.com/instant-alerts/filing-18800-shares-in-hologic-inc-holx-bought-by-pensionfund-sabic-2026-03-25/", "date": "2026-03-25", "summary": "Pensionfund Sabic recently bought 18,800 shares of Hologic, Inc. (NASDAQ:HOLX) for approximately $1.4 million in Q4, adding to significant institutional ownership which stands at 94.73%. Despite this, Hologic reported a Q4 earnings and revenue miss, affecting its stock performance. Analysts currently have a \"Hold\" rating on the stock with an average price target of $78.42.", "sentiment_score": 0.007363, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Hologic, Inc. $HOLX Stake Boosted by Assenagon Asset Management S.A.", "url": "https://www.marketbeat.com/instant-alerts/filing-hologic-inc-holx-stake-boosted-by-assenagon-asset-management-sa-2026-03-25/", "date": "2026-03-25", "summary": "Assenagon Asset Management S.A. significantly increased its stake in Hologic, Inc. by 275.2% in the fourth quarter, bringing its total ownership to 666,053 shares valued at approximately $49.6 million. This increase occurred despite Hologic missing its Q4 earnings and revenue estimates and analysts maintaining a \"Hold\" rating with an average price target of $78.42. The article notes that institutional investors collectively own 94.73% of Hologic's stock.", "sentiment_score": -0.209195, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.612, "confidence": 0.61 } }, { "source": "alpha_vantage", "title": "Therapy animals will reach 100,000 patients and care teams in pilot", "url": "https://www.stocktitan.net/news/BAX/pet-partners-and-the-baxter-foundation-expand-therapy-animal-h1e4g24dsxje.html", "date": "2026-03-25", "summary": "Pet Partners and the Baxter Foundation (NYSE: BAX) have launched a two-year pilot program to expand therapy animal visits, aiming to reach 100,000 patients and healthcare workers in three key U.S. regions. This initiative seeks to reduce stress and improve resilience by providing resources, training, and volunteer support, building on the proven benefits of human-animal interaction in healthcare settings. The program also includes research to further understand the impact of therapy animals on h", "sentiment_score": 0.245017, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.61699, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Thermo Fisher completes $8.9B buyout of Clario", "url": "https://www.medtechdive.com/news/thermo-fisher-completes-89b-buyout-of-clario/815638/", "date": "2026-03-25", "summary": "Thermo Fisher Scientific has finalized its $8.9 billion acquisition of Clario, enhancing its capabilities in clinical trial endpoint data management. By integrating Clario's data capture and interpretation technology with its existing biological sample analysis, Thermo Fisher aims to create a unified, high-growth solution for drug developers. The deal, which includes potential earn-out payments, received approval from the European Commission with minimal competition concerns and is part of Therm", "sentiment_score": 0.116808, "sentiment_label": "Neutral", "relevance_score": 0.6178, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "HOLX or ALGN: Which Medical Technology Stock Should You Choose for Investment Right Now?", "url": "https://www.bitget.com/amp/news/detail/12560605303579", "date": "2026-03-25", "summary": "This article compares two prominent medical technology companies, Hologic (HOLX) and Align Technology (ALGN), for investment potential. While Hologic's diagnostics segment faces challenges and a pending privatization deal offers minimal upside, Align Technology demonstrates strong growth in its clear aligner business with positive analyst sentiment and an attractive valuation, suggesting it's the more favorable investment.", "sentiment_score": -0.400716, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "HOLX vs. ALGN: Which MedTech Stock Is the Better Investment Pick Now?", "url": "https://www.tradingview.com/news/zacks:08917ea12094b:0-holx-vs-algn-which-medtech-stock-is-the-better-investment-pick-now/", "date": "2026-03-25", "summary": "This article provides a comparative analysis of two MedTech companies, Hologic (HOLX) and Align Technology (ALGN), discussing their market positions, recent performance, and future prospects. It concludes that Align Technology is a better investment due to strong Clear Aligner volume growth, strategic progress with DSOs, and positive analyst sentiment, while Hologic's limited upside from its buyout deal and declining COVID testing sales make it a less attractive option for current shareholders.", "sentiment_score": 0.090609, "sentiment_label": "Neutral", "relevance_score": 0.939448, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Hologic upgraded at Evercore ISI on growth turnaround", "url": "http://www.msn.com/en-us/money/markets/hologic-upgraded-at-evercore-isi-on-growth-turnaround/ar-AA1O1Kj2?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-22", "summary": "Evercore ISI upgraded Hologic's stock rating, citing expectations for a growth turnaround and an improved financial outlook for the company. This positive outlook from the analytical firm suggests confidence in Hologic's future performance.", "sentiment_score": 0.428821, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.582, "confidence": 0.58 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-06", "url": "https://www.sec.gov/Archives/edgar/data/859737/000114036126013235/0001140361-26-013235-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider", "description": "Molecular diagnostics market to grow from $18.26 Bn to $43.50 Bn by 2035, driven by PCR, NGS, and demand for early, precise diagnosis....", "url": "https://www.globenewswire.com/news-release/2026/04/03/3267957/0/en/Molecular-Diagnostics-Market-Size-is-Expected-to-Reach-USD-43-50-Billion-by-2035-Owing-to-the-Surging-Demand-for-Accurate-and-Early-Disease-Detection-Globally-SNS-Insider.html", "date": "2026-04-03", "published_at": "2026-04-03T09:00:00Z", "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Mammography Workstation Market to Grow by $500 Million During 2026-2030 Led by Siemens Healthineers, Fujifilm, and Koninklijke Philips", "description": "The market is set for strong growth with the integration of advanced imaging technologies and software-centric solutions The market is set for strong growth with the integration of advanced imaging technologies and software-centric solutions", "url": "https://www.globenewswire.com/news-release/2026/04/01/3266486/28124/en/Mammography-Workstation-Market-to-Grow-by-500-Million-During-2026-2030-Led-by-Siemens-Healthineers-Fujifilm-and-Koninklijke-Philips.html", "date": "2026-04-01", "published_at": "2026-04-01T11:01:00Z", "sentiment": { "label": "positive", "score": 1.0, "confidence": 1.0 } }, { "source": "news", "source_name": "Plos.org", "title": "Genotypic distribution and molecular epidemiology of HPV in women in the UAE using PNA-based RT PCR", "description": "Objectives This study aimed to determine the genotypic distribution and molecular epidemiology of HPVs in PAP smear samples of women in the UAE using a peptide nucleic acid (PNA)-based fluorescence melting curve analysis method. Methods A cross-sectional re…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346052", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook", "description": "Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and liquid biopsy tech Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and li…", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264368/28124/en/Oncology-Biomarkers-Market-Trends-and-Investment-Opportunities-Report-2026-2030-Global-Regional-and-Country-Level-Outlook.html", "date": "2026-03-30", "published_at": "2026-03-30T08:58:00Z", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Devices: Markets and Companies Analysis Report 2026 - Eckert & Ziegler BEBIG, Oncura, GE Healthcare Lead the $210 Billion Industry; Expected to Reach $397 Billion by 2030", "description": "Expansion in personalized treatments, outpatient facilities, AI diagnostics, precision therapies, and innovations in chemotherapy & diagnostics fuel the market Expansion in personalized treatments, outpatient facilities, AI diagnostics, precision therapies, a…", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264356/28124/en/Oncology-Devices-Markets-and-Companies-Analysis-Report-2026-Eckert-Ziegler-BEBIG-Oncura-GE-Healthcare-Lead-the-210-Billion-Industry-Expected-to-Reach-397-Billion-by-2030.html", "date": "2026-03-30", "published_at": "2026-03-30T08:31:00Z", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "Financial Post", "title": "Inside ‘Project Eagle,’ JPMorgan’s High-Wire Act to Fund EA Deal", "description": "The post from @realDonaldTrump landed at precisely 7:23 a.m. Inside JPMorgan Chase & Co., the final piece of Project Eagle was a go.", "url": "https://financialpost.com/pmn/business-pmn/inside-project-eagle-jpmorgans-high-wire-act-to-fund-ea-deal", "date": "2026-03-28", "published_at": "2026-03-28T19:38:06Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Mammography Devices Market to Reach $3.81 Billion by 2030, Driven by Technological Advancements and Rising Breast Cancer Awareness", "description": "Key market opportunities include advancements in digital and 3D mammography, integration of AI and CAD systems, expansion of portable units, and increased government support for early breast cancer detection. Growth in Asia-Pacific and rising breast cancer pr…", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263847/28124/en/Mammography-Devices-Market-to-Reach-3-81-Billion-by-2030-Driven-by-Technological-Advancements-and-Rising-Breast-Cancer-Awareness.html", "date": "2026-03-27", "published_at": "2026-03-27T14:30:00Z", "sentiment": { "label": "negative", "score": -0.727, "confidence": 0.73 } }, { "source": "news", "source_name": "Pehub.com", "title": "Women’s health ripe for private equity investments, finds Kearney’s Paula Bellostas Muguerza", "description": "Blackstone and TPG's $18.3bn take-private of Hologic, which is expected to close soon, is a bellwether.\nThe post Women’s health ripe for private equity investments, finds Kearney’s Paula Bellostas Muguerza appeared first on PE Hub.", "url": "https://www.pehub.com/?p=20000003725583", "date": "2026-03-26", "published_at": "2026-03-26T16:00:53Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "dicom-hl7-mcp added to PyPI", "description": "DICOM/HL7 Developer AI Assistant — MCP server for healthcare integration engineers", "url": "https://pypi.org/project/dicom-hl7-mcp/", "date": "2026-03-25", "published_at": "2026-03-25T17:27:47Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "New York Post", "title": "Iga Swiatek parts ways with tennis coach after stunning loss: ‘Worst nightmare’", "description": "Polish tennis star Iga Swiatek has parted ways with her coach, Wim Fissette, who joined in her 2024, after a \"nightmare\" second-round loss at the 2026 Miami Open.", "url": "https://nypost.com/2026/03/23/sports/iga-swiatek-parts-ways-with-tennis-coach-after-stunning-loss-worst-nightmare/", "date": "2026-03-23", "published_at": "2026-03-23T20:55:06Z", "sentiment": { "label": "negative", "score": -0.45, "confidence": 0.45 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Biopsy Devices Market Size Projected to Reach USD 5.08 Billion by 2035; Increasing Incidence of Cancer to Drive Market Growth Globally – SNS Insider", "description": "Rising Demand for Minimally Invasive, Image-Guided Procedures and Expanding Healthcare Infrastructure Accelerate Global Market Expansion. Rising Demand for Minimally Invasive, Image-Guided Procedures and Expanding Healthcare Infrastructure Accelerate Global M…", "url": "https://www.globenewswire.com/news-release/2026/03/20/3259711/0/en/Biopsy-Devices-Market-Size-Projected-to-Reach-USD-5-08-Billion-by-2035-Increasing-Incidence-of-Cancer-to-Drive-Market-Growth-Globally-SNS-Insider.html", "date": "2026-03-20", "published_at": "2026-03-20T12:14:00Z", "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "U.S. Exosomes Market to Skyrocket During 2026-2033, Reaching $716.8 Million - Analysis of Lucrative Business Opportunities and Key Players; Danaher, Thermo Fisher Scientific, Hologic, Fujifilm, Lonza and More", "description": "Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The \"U.S. Exosomes Market Size, Share & Trends Analysis Report by Product & Service, Application, Workflow, End Use, and Segment Forecasts, 2026-2033\" has been added to ResearchAndMarkets.com's offering.The U.S. exos…", "url": "https://www.globenewswire.com/news-release/2026/03/20/3259642/28124/en/U-S-Exosomes-Market-to-Skyrocket-During-2026-2033-Reaching-716-8-Million-Analysis-of-Lucrative-Business-Opportunities-and-Key-Players-Danaher-Thermo-Fisher-Scientific-Hologic-Fujif.html", "date": "2026-03-20", "published_at": "2026-03-20T10:45:00Z", "sentiment": { "label": "positive", "score": 0.681, "confidence": 0.68 } }, { "source": "news", "source_name": "Forbes", "title": "Why Alexandra Eala Could Be Tennis’ Next Global Trailblazer", "description": "This story is about Alexandra Eala, seeded No. 31 at the Miami Open, and her potential to become the next trailblazing superstar in tennis.", "url": "https://www.forbes.com/sites/merlisalawrencecorbett/2026/03/19/why-alexandra-eala-could-be-tennis-next-global-trailblazer/", "date": "2026-03-19", "published_at": "2026-03-19T20:23:40Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Nature.com", "title": "AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial", "description": "The breast cancer screening trial found that using automated artificial intelligence to triage and support decisions in mammography and digital breast tomosynthesis was not noninferior to double reading.", "url": "https://www.nature.com/articles/s41591-026-04277-x", "date": "2026-03-19", "published_at": "2026-03-19T00:00:00Z", "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "news", "source_name": "Plos.org", "title": "Association between vaginal washing and group B Streptococcus colonization from periconception through the first trimester of pregnancy in a cohort of Kenyan women", "description": "Introduction Vaginal washing has been associated with adverse reproductive health outcomes including pelvic inflammatory disease, reduced fecundability, and HIV acquisition. This analysis tested the hypothesis that vaginal washing is associated with increased…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0344736", "date": "2026-03-18", "published_at": "2026-03-18T14:00:00Z", "sentiment": { "label": "negative", "score": -0.161, "confidence": 0.16 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Is Hologic Stock Outperforming the Dow?", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_19e412a8-8d41-4673-889f-d27d85333fe7", "date": "2026-03-18", "published_at": "2026-03-18T13:59:04Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "Gallup.com", "title": "Global Women's Health Shows Signs of Progress; Gaps Remain", "description": "The fifth Hologic Global Women's Health Index shows progress in preventive care and safety, but gaps remain.", "url": "https://news.gallup.com/poll/702947/global-women-health-shows-signs-progress-gaps-remain.aspx", "date": "2026-03-17", "published_at": "2026-03-17T04:01:00Z", "sentiment": { "label": "positive", "score": 0.7, "confidence": 0.7 } }, { "source": "news", "source_name": "Cdc.gov", "title": "Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026", "description": "This report describes interim estimates of 2025-26 seasonal flu vaccine effectiveness.", "url": "https://www.cdc.gov/mmwr/volumes/75/wr/mm7509a2.htm", "date": "2026-03-12", "published_at": "2026-03-12T17:23:11Z", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global In Vitro Diagnostics Market to Reach USD 157.63 Billion by 2030 | MarketsandMarkets™", "description": "Market Expansion Accelerates as Clinical Laboratories and Healthcare Systems Prioritize Rapid Diagnostics, Automation, and Early Disease Detection Market Expansion Accelerates as Clinical Laboratories and Healthcare Systems Prioritize Rapid Diagnostics, Autom…", "url": "https://www.globenewswire.com/news-release/2026/03/12/3254849/0/en/Global-In-Vitro-Diagnostics-Market-to-Reach-USD-157-63-Billion-by-2030-MarketsandMarkets.html", "date": "2026-03-12", "published_at": "2026-03-12T14:30:00Z", "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "description": "Opportunities in the COVID-19 tests market include developing innovative products, leveraging global and regional trends, understanding competitive dynamics, and accessing country-specific regulatory and reimbursement insights. Companies can capitalize on mar…", "url": "https://www.globenewswire.com/news-release/2026/03/12/3254589/28124/en/COVID-19-Tests-Market-Report-2025-Segments-Share-Regulatory-Reimbursement-and-Forecasts-to-2036.html", "date": "2026-03-12", "published_at": "2026-03-12T12:04:00Z", "sentiment": { "label": "positive", "score": 0.859, "confidence": 0.86 } }, { "source": "news", "source_name": "Nature.com", "title": "A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions", "description": "Genome-wide analysis coupled with long-read sequencing identifies a repeat expansion in GOLGA8A associated with high risk for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.", "url": "https://www.nature.com/articles/s41588-026-02537-7", "date": "2026-03-12", "published_at": "2026-03-12T00:00:00Z", "sentiment": { "label": "negative", "score": -0.541, "confidence": 0.54 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Biomarker Testing Market Projected to Reach USD 50.76 Billion by 2035, Driven by Personalized Medicine and Oncology Advancements – SNS Insider", "description": "The global market, valued at USD 32.69 billion in 2025, is set to grow at a CAGR of 4.51% as demand for early disease detection and precision diagnostics surges worldwide. The global market, valued at USD 32.69 billion in 2025, is set to grow at a CAGR of 4.5…", "url": "https://www.globenewswire.com/news-release/2026/03/10/3252520/0/en/Biomarker-Testing-Market-Projected-to-Reach-USD-50-76-Billion-by-2035-Driven-by-Personalized-Medicine-and-Oncology-Advancements-SNS-Insider.html", "date": "2026-03-10", "published_at": "2026-03-10T09:24:00Z", "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global Point-of-Care Molecular Diagnostics Market Projected to Reach USD 13.05 Billion by 2035; Growth is Driven by Increasing Need for Fast Near-Patient Testing Globally – SNS Insider", "description": "Growing Adoption of PCR-Based Platforms, Isothermal Amplification Technologies, and Lab-on-a-Chip Systems Accelerating Market Expansion Globally. Growing Adoption of PCR-Based Platforms, Isothermal Amplification Technologies, and Lab-on-a-Chip Systems Acceler…", "url": "https://www.globenewswire.com/news-release/2026/03/09/3251747/0/en/Global-Point-of-Care-Molecular-Diagnostics-Market-Projected-to-Reach-USD-13-05-Billion-by-2035-Growth-is-Driven-by-Increasing-Need-for-Fast-Near-Patient-Testing-Globally-SNS-Inside.html", "date": "2026-03-09", "published_at": "2026-03-09T11:51:00Z", "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "pubmed", "pmid": "41938839", "title": "Development of an early prediction model for endometriosis risk: the simplified adolescent factors for endometriosis (SAFE) score.", "authors": "Mishra GD et al.", "journal": "EClinicalMedicine", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41938839/", "sentiment": { "label": "positive", "score": 0.368, "confidence": 0.37 } }, { "source": "pubmed", "pmid": "41937539", "title": "It Is All About Energy-the Changing Role of X-ray Photons in Photon-counting Detector Computed Tomography: What the Radiologist Needs to Know About kV and keV.", "authors": "Hoeijmakers EJI et al.", "journal": "Investigative radiology", "date": "2026 Apr 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41937539/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41936820", "title": "Validation of a Low-Volume (100 μL) Plasma Protocol for HIV-1 RNA Quantification Using the Hologic Aptima HIV-1 Quant Dx Assay.", "authors": "Madurai LS et al.", "journal": "The Journal of molecular diagnostics : JMD", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41936820/", "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "pubmed", "pmid": "41931983", "title": "Can large language models like ChatGPT and Gemini interpret cervical cytology accurately?", "authors": "Geetha SD", "journal": "Annals of diagnostic pathology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41931983/", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "pubmed", "pmid": "41930568", "title": "Prediction of spontaneous onset of labor at term using clinical, ultrasound, and biochemical data: A multicenter prospective observational study (the PREDICT study).", "authors": "Migliorelli F et al.", "journal": "Acta obstetricia et gynecologica Scandinavica", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41930568/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41927463", "title": "Point-of-care testing for chlamydia and gonorrhoea: a narrative review of patient perspectives and implementation into non-traditional settings.", "authors": "Griner SB et al.", "journal": "Sexually transmitted infections", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41927463/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41926089", "title": "Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.", "authors": "Park CS et al.", "journal": "JAMA oncology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41926089/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41925922", "title": "Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.", "authors": "Hörner M et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41925922/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41925307", "title": "Development and evaluation of dried urine strip for genital chlamydia and gonorrhea testing.", "authors": "Gibbons S et al.", "journal": "Journal of clinical microbiology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41925307/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41920021", "title": "Longitudinal Deterioration in Nutritional Status Associated With Increased Risk of Sarcopenia in Community-Dwelling Aged Adults: A Prospective Cohort Study.", "authors": "Lim HJ et al.", "journal": "Journal of cachexia, sarcopenia and muscle", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41920021/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41918854", "title": "Treatment Approaches for Refractory Mycoplasma genitalium Infection.", "authors": "Tenney R et al.", "journal": "Open forum infectious diseases", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41918854/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41915825", "title": "The Vaginal Microbiota in Pig-Tailed Macaques and Colonization with Neisseria gonorrhoeae.", "authors": "Srinivasan S et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41915825/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41914308", "title": "Cervical Cancer Elimination in Australia and the Asia Pacific: Progress and Barriers.", "authors": "Yuill S et al.", "journal": "The Medical journal of Australia", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41914308/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41913316", "title": "Psychosocial Burden of Women With Cervical Intraepithelial Neoplasia in Japan: Results of A Web-Based Survey.", "authors": "Sato K et al.", "journal": "The journal of obstetrics and gynaecology research", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41913316/", "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41907870", "title": "Prospective Multicenter Evaluation of Patient Satisfaction and Radiologist Image Interpretation Using the Envision™ Mammography Platform.", "authors": "Parghi CR et al.", "journal": "Medical devices (Auckland, N.Z.)", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41907870/", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41885612", "title": "Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination.", "authors": "Kachikis A et al.", "journal": "The Journal of infectious diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41885612/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41885439", "title": "Positive nucleic acid amplification test results are rarely indicative of a viable rectal Chlamydia trachomatis infection among men with anal exposures other than receptive anal sex.", "authors": "Khosropour CM et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41885439/", "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "pubmed", "pmid": "41878523", "title": "Dual-modality CAD for breast cancer screening: dealing with discordant diagnosis between mammography and tomography.", "authors": "Beaumont H et al.", "journal": "Frontiers in oncology", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41878523/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874876", "title": "Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.", "authors": "Jeng A et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874876/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874107", "title": "Estimating the sensitivity of non-treponemal and treponemal antibody tests in primary syphilis.", "authors": "Sweitzer SF et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874107/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41861507", "title": "Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use: the SHARP-P study.", "authors": "Conway A et al.", "journal": "The International journal on drug policy", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861507/", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41858246", "title": "Unsatisfactory ThinPrep Pap Tests: An Educational Approach to Quality.", "authors": "Olson K et al.", "journal": "Diagnostic cytopathology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41858246/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41856415", "title": "BlotDx: A deep learning tool for Western blot-based diagnostics.", "authors": "Liu L et al.", "journal": "Journal of virological methods", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41856415/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41852862", "title": "Management and Outcomes of Complications Related to BioZorb Use in Breast-Conserving Surgery: A Retrospective Single-Center Case Series Analysis.", "authors": "Baz C et al.", "journal": "Ochsner journal", "date": "2026 Sprin", "url": "https://pubmed.ncbi.nlm.nih.gov/41852862/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41849329", "title": "Association between vaginal washing and group B Streptococcus colonization from periconception through the first trimester of pregnancy in a cohort of Kenyan women.", "authors": "Jisuvei CS et al.", "journal": "PloS one", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41849329/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41825191", "title": "2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States.", "authors": "Irving SA et al.", "journal": "Vaccine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41825191/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41820630", "title": "Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.", "authors": "Kanis JA et al.", "journal": "Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41820630/", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "pubmed", "pmid": "41820501", "title": "Clinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer.", "authors": "Van Keer S et al.", "journal": "Communications medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41820501/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41818161", "title": "Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.", "authors": "Maloney P et al.", "journal": "MMWR. Morbidity and mortality weekly report", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41818161/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41817930", "title": "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.", "authors": "Kuemmel S et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41817930/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41806477", "title": "A 3D-printed anthropomorphic breast phantom with realistic anatomy and attenuation properties for spatially resolved dosimetry in mammography.", "authors": "Liu Y et al.", "journal": "Physics in medicine and biology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41806477/", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "pubmed", "pmid": "41806049", "title": "Task-Based Sampling of Patient Data for Rigorous Machine Learning/AI Performance Assessment.", "authors": "Baughan N et al.", "journal": "Journal of imaging informatics in medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41806049/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41801760", "title": "Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.", "authors": "Wang L et al.", "journal": "JAMA", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41801760/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41747748", "title": "Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.", "authors": "Ndung'u T et al.", "journal": "The lancet. HIV", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41747748/", "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "pubmed", "pmid": "41719678", "title": "Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States.", "authors": "Mahtani R et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41719678/", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41707479", "title": "Late distant recurrence prediction model in premenopausal women with ER-positive/HER 2-negative breast cancer: A multicenter retrospective study.", "authors": "Shin DS et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41707479/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41689946", "title": "Clinicopathologic characteristics and lymph node status in the NAUTILUS clinical trial:KBCSG-21.", "authors": "Ryu JM et al.", "journal": "European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41689946/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41679383", "title": "Agreement and systematic difference between bioelectrical impedance analysis and dual-energy X-ray absorptiometry for appendicular lean mass in 1617 community-dwelling older adults: The Bunkyo Health Study.", "authors": "Nakagata T et al.", "journal": "Clinical nutrition ESPEN", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41679383/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41651703", "title": "The global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic review.", "authors": "Degenhardt L et al.", "journal": "The International journal on drug policy", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41651703/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41651702", "title": "Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review.", "authors": "Santo T Jr et al.", "journal": "The International journal on drug policy", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41651702/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41637791", "title": "Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.", "authors": "O'Regan RM et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41637791/", "sentiment": { "label": "negative", "score": -0.898, "confidence": 0.9 } }, { "source": "pubmed", "pmid": "41589842", "title": "Emergence of influenza A(H3N2) subclade K in northeast Ohio in autumn 2025.", "authors": "Xu X et al.", "journal": "Journal of clinical microbiology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41589842/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41504632", "title": "DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.", "authors": "Jhaveri K et al.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41504632/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41489384", "title": "Evaluation of Alinity m STI Assay for Simultaneous Detection of Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis , and Mycoplasma genitalium in Female Urogenital Specimens.", "authors": "Gentil LG et al.", "journal": "Sexually transmitted diseases", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41489384/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41427726", "title": "Evaluation of Alinity m Sexually Transmitted Infection Assay for Simultaneous Detection of Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis , and Mycoplasma genitalium in Male Urine Specimens.", "authors": "Cullum R et al.", "journal": "Sexually transmitted diseases", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41427726/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41401234", "title": "Diagnostic accuracy and prognostic value of CMR in patients with suspected acute coronary syndrome: a meta-analysis.", "authors": "van Cauteren YJM et al.", "journal": "European heart journal. Cardiovascular Imaging", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41401234/", "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "pubmed", "pmid": "41396705", "title": "Dual Treponemal and Non-Treponemal Rapid Test for Syphilis in People Living with HIV: A Diagnostic Accuracy Study.", "authors": "Fuertes-Bucheli JF et al.", "journal": "Sexually transmitted diseases", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41396705/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41334895", "title": "Commercial Artificial Intelligence (AI) Tool for Screening Digital Breast Tomosynthesis: Factors Associated With AI-Based Breast Cancer Detection.", "authors": "Bahl M et al.", "journal": "AJR. American journal of roentgenology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41334895/", "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41192692", "title": "Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD.", "authors": "Jachs M et al.", "journal": "Journal of hepatology", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41192692/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41109867", "title": "Computed tomography pulmonary angiography in around-the-clock clinical care with individualised scan protocols: a 5-year observational study on incidence and causes of repeat scanning.", "authors": "Nijssen EC et al.", "journal": "European radiology", "date": "2026-04-07", "url": "https://pubmed.ncbi.nlm.nih.gov/41109867/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } } ] } }